Payment overview · 2025
General Payments
$400.07
22 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph Fredrick Morris, MD
Allopathic & Osteopathic Physicians|Family Medicine · NICHOLASVILLE, KY · NPI 1477667269
Verified facts
What the public records show
CMS Open Payments records show Joseph Fredrick Morris, MD received $400.07 in general payments during 2025 across 22 reported records.
Novartis Pharmaceuticals Corporation accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $102.12 | 25.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.72 | 18.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.11 | 13.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.87 | 12.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.82 | 8.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.74 | 8.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.12 | 6.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.45 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.12 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $400.07 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $102.12 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.72 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.87 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.87 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 116 |
| Losartan Potassium | Losartan Potassium | 291 | 92 |
| Lisinopril | Lisinopril | 289 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 78 |
| Gabapentin | Gabapentin | 198 | 36 |
| Metformin Hcl | Metformin Hcl | 174 | 58 |
| Omeprazole | Omeprazole | 153 | 57 |
| Famotidine | Famotidine | 146 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 46 |
| Furosemide | Furosemide | 119 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 49 |
| Ozempic | Semaglutide | 117 | 23 |
| Chlorthalidone | Chlorthalidone | 115 | 41 |
| Meloxicam | Meloxicam | 110 | 40 |
| Carvedilol | Carvedilol | 109 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 37 |
| Potassium Chloride | Potassium Chloride | 94 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 24 |
| Montelukast Sodium | Montelukast Sodium | 75 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 23 |
| Eliquis | Apixaban | 71 | 20 |
| Jardiance | Empagliflozin | 70 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Sertraline Hcl | Sertraline Hcl | 67 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 22 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 19 |
| Simvastatin | Simvastatin | 52 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Nifedipine Er | Nifedipine | 49 | 13 |
| Spironolactone | Spironolactone | 48 | 16 |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Entresto | Sacubitril/Valsartan | 43 | 12 |
| Azithromycin | Azithromycin | 41 | 34 |
| Allopurinol | Allopurinol | 38 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 11 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Cefdinir | Cefdinir | 23 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Glipizide | Glipizide | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Baclofen | Baclofen | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Rayaldee | Calcifediol | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.07 · 22 records | Novartis Pharmaceuticals Corporation | AREXVY, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, MINIMED 780G, Omnipod, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error